Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shukra PharmaceuticalsBOM:524632 -1.63%66 Gross Margin % is 6.07% as of Mar. 2026, which is 92% below its 10-year median of 74.89. GuruFocus rates BOM:524632 with a GF Score™ of 66/100 and a GF Value™ of ₹8.67 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Shukra Pharmaceuticals ranks better than 84.52% on this metric.
BOM:524632's Gross Margin % is ranked better than 84.52% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:524632: 72.06
Shukra Pharmaceuticals had a gross margin of 6.07% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Shukra Pharmaceuticals was 4.70% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Shukra Pharmaceuticals had a gross margin of 6.07% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Shukra Pharmaceuticals Gross Margin % Related Terms
Shukra Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Shukra Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524632 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shukra Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Shukra Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Shukra Pharmaceuticals (BOM:524632) has a Gross Margin % of 6.07% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Shukra Pharmaceuticals and its competitors. This is 92% below median its historical median of 74.89. Over the past decade, Shukra Pharmaceuticals' Gross Margin % has ranged from 22.97 to 82.50. According to the industry distribution chart, Shukra Pharmaceuticals ranks #146 out of 943 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is Shukra Pharmaceuticals' Gross Margin % too high?
Shukra Pharmaceuticals' current Gross Margin % of 6.07% is 92% below median its 10-year median of 74.89. Over the past 10 years, this metric has ranged from a low of 22.97 to a high of 82.50. The Drug Manufacturers industry median Gross Margin % is 48.54. Shukra Pharmaceuticals' value of 6.07% is 87.5% below this industry median. Based on the distribution chart, Shukra Pharmaceuticals ranks #146 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shukra Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shukra Pharmaceuticals ranks #146 out of 943 companies for Gross Margin %. This places Shukra Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Shukra Pharmaceuticals' value of 6.07% is 87.5% below this benchmark. Historically, Shukra Pharmaceuticals' own Gross Margin % has ranged from 22.97 to 82.50 over the past decade. While the company's 10-year median is 74.89 vs. the industry median of 48.54, Shukra Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shukra Pharmaceuticals's current Gross Margin % of 6.07% is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Shukra Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shukra Pharmaceuticals's current Gross Margin % is 6.07%, which is 92% below median its own 10-year median of 74.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.67, compared to a current price of ₹33.89 — trading 290.9% above its estimated fair value. The current Gross Margin % is 6.07%, which is 92% below median its 10-year median of 74.89 and 87.5% below the Drug Manufacturers industry median of 48.54. Shukra Pharmaceuticals' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Gross Margin % is 6.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?
Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹33.89 is trading 290.9% above its estimated GF Value™ of ₹8.67.
GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524632:
Gross Margin %: 6.07% (92% below median its 10-year median of 74.89)
GF Value™: ₹8.67 vs. price of ₹33.89 (290.9% above fair value)
Industry Position: 87.5% below the Drug Manufacturers median (#146 of 943)
No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
66GF Score
Get the complete analysis for BOM:524632
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524632 has been successfully added to your 
